Market closed
Cogent Biosciences/$COGT
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Cogent Biosciences
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling.
Ticker
$COGT
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
164
Website
COGT Metrics
BasicAdvanced
$900M
Market cap
-
P/E ratio
-$2.48
EPS
-0.05
Beta
-
Dividend rate
Price and volume
Market cap
$900M
Beta
-0.05
52-week high
$12.11
52-week low
$4.28
Average daily volume
1.8M
Financial strength
Current ratio
6.438
Quick ratio
6.325
Long term debt to equity
5.183
Total debt to equity
5.666
Management effectiveness
Return on assets (TTM)
-44.02%
Return on equity (TTM)
-78.47%
Valuation
Price to book
4.41
Price to tangible book (TTM)
4.41
Price to free cash flow (TTM)
-4.148
Growth
Earnings per share change (TTM)
5.46%
3-year earnings per share growth (CAGR)
-20.48%
What the Analysts think about COGT
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Cogent Biosciences stock.
COGT Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
COGT Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
COGT News
AllArticlesVideos
Cogent Biosciences Announces Updated Clinical Results from SUMMIT, Showcasing Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis Patients
GlobeNewsWire·6 days ago
Cogent Biosciences Announces Positive Updated Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
GlobeNewsWire·7 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Cogent Biosciences stock?
Cogent Biosciences (COGT) has a market cap of $900M as of December 15, 2024.
What is the P/E ratio for Cogent Biosciences stock?
The price to earnings (P/E) ratio for Cogent Biosciences (COGT) stock is 0 as of December 15, 2024.
Does Cogent Biosciences stock pay dividends?
No, Cogent Biosciences (COGT) stock does not pay dividends to its shareholders as of December 15, 2024.
When is the next Cogent Biosciences dividend payment date?
Cogent Biosciences (COGT) stock does not pay dividends to its shareholders.
What is the beta indicator for Cogent Biosciences?
Cogent Biosciences (COGT) has a beta rating of -0.05. This means that it has an inverse relation to market volatility.